AI solves the pain points of statistical programming in clinical trials, Weikeli Pharmaceutical seeks financing

Clinical statistical programming is a crucial step before drug launch. However, the traditional model highly relies on manual SAS code writing to process massive patient data, which is a long and error - prone process. OpenGraphs, a company dedicated to empowering clinical trial data statistics with AI, is trying to change this situation. Currently, the company is seeking a new round of financing.

OpenGraphs was founded in December 2025 and focuses on providing AI - driven full - process solutions for clinical trials to the global pharmaceutical industry. The company's entry point is one of the most labor - intensive and repetitive aspects of clinical trials: clinical data statistics and analysis programming. The founder and CEO, Weixing Chen, holds a master's degree in biostatistics and epidemiology from the University of Southern California and has a profound understanding of the pain points in the clinical trial data flow. The CTO, Xinrui Wang, is a doctoral student in the field of large models at the University of Tokyo and has the engineering ability of cutting - edge AI technology.

Core pain point: The efficiency bottleneck of statistical programming restricts the launch of new drugs

In drug clinical trials, statistical programmers need to convert massive amounts of raw case data into analysis results for review by drug regulatory agencies using tools such as SAS and R. This process not only requires writing tens of thousands of lines of code but also repeated verification and modification, which takes months. As clinical trial designs become increasingly complex, the manual programming model has become one of the main bottlenecks restricting trial efficiency and driving up R & D costs. The global AI medical market is growing rapidly, and using AI to assist in clinical data analysis is regarded as a definite direction for improving efficiency and reducing costs.

Solution: Use large models to achieve "automatic code generation"

OpenGraphs' first product, the AI data analysis tool, aims to address this pain point. Based on large - language model technology and fine - tuned with professional corpus in the field of clinical statistics, this tool can understand the statistical analysis plan (SAP) and automatically generate statistical analysis code that meets regulatory requirements.

"Our goal is not to replace statisticians but to free programmers from heavy and repetitive coding," said the founder, Weixing Chen. "Ideally, AI can complete 95% of the basic coding work, and humans only need to review and fine - tune. This will greatly shorten the data analysis cycle and reduce the risk of human error."

In addition, the company has a clear five - year product roadmap: starting from the current data analysis tool, it will subsequently launch products such as AI Medical Writer (automatically generating clinical research reports), AI regulatory registration tools, and AI drug safety tools, and ultimately build an AI - assisted platform covering the entire process of clinical trials.

Team background: In - depth integration of industrial experience and AI technology

The team composition is one of the core advantages of OpenGraphs.

· Chief Medical Advisor, Gang Wei: With over 35 years of clinical and pharmaceutical R & D experience, he was formerly the senior medical director of Fosun Pharma's global R & D center and has rich practical experience in the clinical development, registration, and launch of innovative drugs.

· Chief AI Advisor, Yutaka Matsuo: A professor at the University of Tokyo, the chairman of the Japanese AI Strategy Council, and a non - executive director of SoftBank Group, he is one of the most influential academic authorities in the Japanese AI field.

· Core team: It integrates talents from multiple fields such as biostatistics, clinical operations, and large - model algorithms and has the ability to deeply integrate technology with industrial needs.

· 

Business model and market space

The company's target customers are clear, mainly large and medium - sized pharmaceutical companies at home and abroad and CROs (Contract Research Organizations). The business model adopts SaaS subscription + project - based services to provide customers with standardized tools and customized solutions.

The top 20 global pharmaceutical companies spend more than $50 billion annually on clinical trial operations. For every 1% increase in the penetration rate of AI - assisted tools, it means a market space of billions of dollars.

Current progress and plans

The company has completed the product concept verification and is communicating with potential pharmaceutical companies for POC (Proof of Concept) cooperation. This round of financing will be mainly used for:

Product iteration: Complete the product packaging of the AI data analysis tool.

Market verification: Promote pilot cooperation with 2 - 3 leading domestic pharmaceutical companies or CROs.

Team expansion: Focus on recruiting core positions such as clinical data experts and algorithm engineers.

OpenGraphs hopes to start from the least efficient part of clinical trials and use AI to bring real changes to this rigorous and traditional industry.